Novel Input for Designing Patient-Tailored Pulmonary Rehabilitation: Telemonitoring Physical Activity as a Vital Sign-SMARTREAB Study.
IPAQ
physical activity
respiratory diseases
telemonitoring
vital sign
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Jul 2020
31 Jul 2020
Historique:
received:
12
06
2020
revised:
24
07
2020
accepted:
28
07
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
epublish
Résumé
Physical inactivity may be a consequence of chronic diseases but also a potential modifiable risk factor. Therefore, it should be clinically assessed as a vital sign of patients' general physical condition prior to any exercise-based intervention. This cross-sectional study describes physical activity in the daily life of 100 chronic respiratory patients before pulmonary rehabilitation, comparing subjective and objective measures. The assessment combined the International Physical Activity Questionnaire (IPAQ) and 4-day accelerometer and oximeter telemonitoring with SMARTREAB technology, assessing heart rate, transcutaneous oxygen saturation and activity-related energy expenditure by metabolic equivalent of task (MET). According to IPAQ, 49% of patients had a moderate level of physical activity in daily life (PADL), a weekly mean level of 2844 ± 2925 MET.min/week, and a mean sedentary time of 5.8 ± 2.7 h/day. Alongside this, SMARTREAB telemonitoring assessed maximum activity ranging from 1.51 to 4.64 METs, with 99.6% daytime spent on PADL below 3 METs and 93% of patients with daily desaturation episodes. Regardless of the self-reported IPAQ, patients spend at least 70% of daytime on PADL below 2 METs. SMARTREAB was demonstrated to be an innovative methodology to measure PADL as a vital sign, combining oximetry with accelerometry, crossmatched with qualitative patient data, providing important input for designing patient-tailored pulmonary rehabilitation.
Identifiants
pubmed: 32751825
pii: jcm9082450
doi: 10.3390/jcm9082450
pmc: PMC7464888
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : PDE/BDE/127785/2016
Références
J Appl Physiol (1985). 2006 Apr;100(4):1324-31
pubmed: 16322367
Health Sci Rep. 2018 Aug 15;1(10):e84
pubmed: 30623040
Lung. 2019 Aug;197(4):415-425
pubmed: 31154459
BMC Pulm Med. 2015 May 13;15:61
pubmed: 25967368
BMC Pulm Med. 2017 Jul 25;17(1):104
pubmed: 28743305
Int J Behav Nutr Phys Act. 2011 Jul 28;8:79
pubmed: 21798015
Respir Care. 2017 May;62(5):579-587
pubmed: 28270544
Prev Chronic Dis. 2017 Nov 30;14:E123
pubmed: 29191260
Respir Med. 2012 Apr;106(4):522-30
pubmed: 22118987
Respir Res. 2017 Jan 14;18(1):16
pubmed: 28088206
J Phys Act Health. 2016 Nov;13(11):1275-1283
pubmed: 27334811
Int J Chron Obstruct Pulmon Dis. 2015 Feb 26;10:423-8
pubmed: 25750524
Eur Respir J. 2014 Dec;44(6):1521-37
pubmed: 25359358
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Eur Respir J. 2016 Jul;48(1):69-81
pubmed: 27103381
Chron Respir Dis. 2014 Nov;11(4):187-9
pubmed: 25361628
Am J Respir Crit Care Med. 2015 Oct 15;192(8):924-33
pubmed: 26161676
Chron Respir Dis. 2017 Aug;14(3):256-269
pubmed: 28774199
Eur J Epidemiol. 2018 Sep;33(9):811-829
pubmed: 29589226
J Clin Med. 2019 Mar 11;8(3):
pubmed: 30862102
Eur Respir J. 2016 Feb;47(2):410-9
pubmed: 26828055
Chest. 2011 Aug;140(2):331-342
pubmed: 21273294
Clin Transl Allergy. 2013 Jan 15;3(1):1
pubmed: 23320405
Int J Behav Nutr Phys Act. 2018 Feb 8;15(1):15
pubmed: 29422051
Rev Port Pneumol. 2014 May-Jun;20(3):131-7
pubmed: 24418722
Telemed J E Health. 2014 Jul;20(7):626-32
pubmed: 24796364